ArticleOncotarget2017

The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.

Yun Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.